The Competition Commission of India (CCI) feels the proposed merger between two of the country’s leading drug makers, Sun Pharmaceutical Industries and Ranbaxy Laboratories, could lead to “high market concentration” in certain molecules, indicating a possible monopoly in product segments common for both.“This is the first case” of a combination where the CCI has gone for a public scrutiny, said its chairman, Ashok Chawla.

Source - http://www.business-standard.com